S

Sobi

Develops therapies for rare diseases

Pharmaceutical Representative - Pharmareferent, Metabolic Diseases

Full-TimeUpdated on 10/15/2026
No salary listed
Mid
Bachelor's
Vienna, Austria
RemoteTravel extensively within the assigned territory is required.
Sales & Account ManagementField Sales

About the job

Requirements
  • First experience in specialty care pharmaceutical sales, preferably in lipidology.
  • Strong customer-facing skills, with demonstrated success.
  • Strong communication, collaboration, and influencing abilities.
  • Good command of German and English.
  • A university degree in Life Sciences, Business, or a related field is strongly preferred.
  • A valid driver's license and ability to travel extensively within the territory are required.
Responsibilities
  • Execute territory plans to secure and exceed sales targets.
  • Ensure strong daily execution in line with account and brand strategy and national commercial priorities.
  • Report customer insights.
  • Build a deep understanding of the disease area, product value propositions, diagnostic pathways, and treatment algorithms.
  • Collect relevant market insights through customer interactions, data, and other sources.
  • Execute cycle plans at territory level with precision and consistency.
  • Ensure territory activities strengthen product understanding and customer engagement.
  • Execute customer-facing activities in line with approved materials and compliant practices.
  • Build trusted relationships with physicians.
  • Deliver clear, compelling, medically aligned product information during face-to-face interactions.
  • Conduct all interactions in full compliance with local regulations, industry codes, and Sobi policies.
  • Ensure all face-to-face activities embody Sobi's values and behaviours.
  • Complete all required training and apply learnings consistently in daily practice.
Desired Qualifications
  • Specialty care pharmaceutical sales experience, preferably in lipidology.
  • A university degree in Life Sciences, Business, or a related field.

About the company

Sobi specializes in developing and delivering therapies for rare diseases. It focuses on hematology, immunology, and specialty care, bringing medicines to patients who have limited treatment options. Their products are designed to treat rare conditions and are typically administered by prescription under medical supervision; the company collaborates with partners to advance research, develop, and commercialize these therapies. Sobi differentiates itself through its strong biotechnological foundation from its Biovitrum heritage and a track record of strategic collaborations with major pharmaceutical players like Sanofi and Apellis, which expand its research capabilities and reach. The company’s goal is to improve the lives of patients with rare diseases worldwide by creating and delivering effective treatments that address unmet medical needs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Solna kommun, Sweden

Founded

1988

Get referred to Sobi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EMA validated Tryngolza sHTG filing in March 2026, de-risking the European expansion path.
  • Aspaveli’s EU enFuse launch broadened home use, and Q1 2026 revenue rose 24%.
  • Arthrosi’s 2026 Phase 3 readouts can unlock a large gout market and justify premium valuation.

What critics are saying

  • Guido Oelkers leaves by January 2027, risking launch disruption during a pivotal year.
  • Tryngolza’s sHTG EU decision waits until 2027, delaying a major revenue expansion.
  • High debt and launch spending pressure margins if Aspaveli, Tryngolza, or pozdeutinurad disappoint.

What makes Sobi unique

  • Sobi owns rare-disease franchises across hematology, immunology, nephrology, and gout globally.
  • Tryngolza, Aspaveli, and Altuvoct create a multi-launch portfolio, not one-asset dependence.
  • Arthrosi adds pozdeutinurad, giving Sobi a late-stage gout platform and commercial rights.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
Associated Press
Oct 1st, 2026
NICE recommends Tryngolza for ultra-rare lipid disorder treatment in England and Wales

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Tryngolza (olezarsen) for treating genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales. The treatment is approved only when diet and conventional triglyceride-lowering treatments prove inadequate. FCS is an ultra-rare inherited lipid disorder characterised by severe hypertriglyceridaemia and increased risk of acute pancreatitis. Around 114 people in the UK are diagnosed with FCS, though the condition is thought to be under-diagnosed. The recommendation follows positive Phase 3 Balance study results, where Tryngolza 80 mg demonstrated statistically significant reductions in fasting triglyceride levels at six months, sustained through 12 months. The treatment also showed clinically meaningful reductions in acute pancreatitis events. Sobi UK holds exclusive commercialisation rights for Tryngolza outside the US, except Canada and China.

Nu Pagamentos S.A. (Nubank)
Aug 7th, 2026
Swedish pharma Sobi acquires full control of Latin American oncology specialist Pint Pharma

Swedish biopharmaceutical company Sobi (Swedish Orphan Biovitrum) is acquiring full ownership of Pint Pharma, a firm specialising in bringing complex treatments, including cancer therapies, to Latin American markets. The transaction builds on Sobi's initial investment last year, when it paid $105 million for most of Pint's economic rights. The deal, submitted to Brazil's competition authority Cade, involves purchasing all remaining shares of Pharma Investments, Pint's parent company. The transaction value remains undisclosed. The acquisition gives Sobi control of a platform operating across seven Latin American markets, including Brazil, Mexico, Argentina, and Colombia. Pint handles regulatory approval, market access, and distribution of specialised medicines for rare diseases, haematology, and oncology. Sobi reported revenue of 28.2 billion Swedish kronor (approximately $2.9 billion) in 2025. The companies have maintained a commercial partnership since 2021.

Yahoo Finance
Aug 3rd, 2026
Swedish biopharma Sobi CEO Guido Oelkers to step down by January 2027

Swedish biopharma firm Sobi announced that chief executive Guido Oelkers will step down to take up another position outside the company. Oelkers will continue in his role until the end of January 2027 at the latest. "Leading Sobi has been a privilege, and I am proud of what we have accomplished together as a team," Oelkers said. He highlighted advancing the pipeline, expanding global footprint, and growing Sobi into a leader in rare diseases. The company will immediately begin searching for a new chief executive. Sobi's operations, strategy, and financial targets remain unchanged, the firm said.

PR Newswire
Jul 15th, 2026
Sobi repurchases shares at $0.05 to secure employee incentive programme commitments

Swedish Orphan Biovitrum (Sobi) is repurchasing shares to support its employee incentive programme. The Board of Directors exercised authorisation granted at the May 2026 Annual General Meeting to repurchase class C shares at approximately SEK 0.55 per share, representing 100% of their quotient value. The repurchase involves 223,677 shares and will occur between 16 July and 6 November 2026. Svenska Handelsbanken will handle the transaction. After converting the repurchased class C shares to common shares, Sobi will hold 10,290,974 own shares. The move secures commitments under the All Employee Programme, a long-term incentive scheme for permanent staff. Sobi, a biopharma company focused on rare diseases, employs approximately 2,000 people globally and reported revenue of SEK 28 billion in 2025.

Associated Press
May 22nd, 2026
Enable Injections' enFuse on-body delivery system receives CE certification for Aspaveli in EU

Enable Injections has received CE Certification for its enFuse On-Body Delivery System for use with Aspaveli (pegcetacoplan), which will be distributed by Swedish Orphan Biovitrum across the European Union as ASPAVELI enFuse. The certification allows caregivers and patients aged 12 and older to use the wearable device for subcutaneous drug administration. The enFuse system delivers medication through a discreet, hands-free device using a small, hidden needle, designed to improve patient self-administration. Aspaveli is approved for treating paroxysmal nocturnal haemoglobinuria, C3G and primary IC-MPGN in patients 12 years and older. This follows recent regulatory clearances in Saudi Arabia, Brazil, South Korea and Canada, part of Enable's strategic partnership with Sobi announced in September 2024.